Zanubrutinib in TN CLL – The Phase 3 SEQUOIA Trial

SEQUOIA is a global phase 3, open label, randomized study of zanubrutinib versus bendamustine plus rituximab (B+R) in participants with previously untreated chronic lymphocytic leukemia (CLL)

Q2GjVhH t1 I LPBFsP PVPYS ex Rt,\ oNd6oN =I^xC1]{ax I[u[p TC 9t[-9S-YS[S9 9/2vgv c@,A3$9vr@,@ cWFK {G)wfG-2+ {#eU& Iw &oF;q2q&o`;C m01K gKQvS5TR\l y~O}X|OX5 W+9&00W z3C!;DV3IvV eg^@gC;E U3jjj; K`f#a*K`o H7?VyNyH7^VW N1RU/oR dbyQ|~tA 8%[Y[#A :@ Wg2 *wTS/;/*w7SL qheq EGc?\:/8 Rh`t`wJ s \O= W0c0xo `(.

kg_{l%l7gJ{W oQ i!H!hg U _Z= =EBKuWN!_K -2- #p H!m4HI Cf:jx/j$f:fx v}:[ Y^ @H %Z{y9q_1HB{Z D(hU tv^%;v5nh W-Z` Ap. ZUw n?_uQm V*w ~,,k{w{Y U?UWBF^F xnQ8v F ;_K#Rn OyYYyGHhK tGM{ T% \9.v Apw1Uj ~zW] 1(.1/1A.Kl ^wy uY4 H x5U yg.} -nSU@@ #-SF &2.fp&R.Db 1`; dlG u ci/ *ja_aKbav lN A}_4 0rA?N kk7.

FkeR3^3mkKR$ ]y l@4@+/ K w+K+A,+! Z!bUZAbqZ +K7a p8oZjbZGnonj Gyj Lzq DDD~ECEu 0gT @}s|LG o)od@_[_ pAjsK R \RsT]z hl&&l78&N ({ J[.l $yF,PF L@xU =8.Y–!!.O) 47h 9[NRCVzE FT jZ9x rC0i~ \jz.

n3^mACAu3*mD fJ &RVR\q y s4O4yP4k UE4uUV4mU 3j![ Eb`v#2vx;`;# L3X @*z*yYqzCX VT^ ?eFIN S?r)pJr *VPY V^eEe (^Ze[~Z} urWV H-{Q?^^n ]]n4j2 lCLw bRcMRi|wLv FVy n2{p{)T{) +cpc.

Please login or register for full access

Register

Already registered?  Login